Namuscla

Namuscla is a medicine used to treat symptoms of myotonia (muscle stiffness) in children aged 6 to 11 years weighing at least 20 kg, adolescents aged 12 to 17 years and adults with non\-dystrophic myotonic disorders, a group of inherited muscle disorders. Non\-dystrophic means no muscle wasting occurs in patients affected by the condition. Patients with non\-dystrophic myotonic disorders experience muscle stiffness and pain because their muscles are slow to relax after contraction. Myotonic disorders are rare, and Namuscla was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 November 2014\.